With the right investment policies, such manufacturers could expand to export quality vaccines into regional markets and progressively integrate their manufacturing processes to move into R&D.
Almost 30 African countries, including South Africa, which get billions of dollars in HIV/Aids funding from the US government, now have a greater role in the planning and implementation of these programmes to end HIV/Aids by 2030.